This is the authors' abstract. We don't add key points for this paper.
This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.
No takes yet. Share an insight, caveat, or question.
Haslam et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: